MX358636B - Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. - Google Patents

Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas.

Info

Publication number
MX358636B
MX358636B MX2012008300A MX2012008300A MX358636B MX 358636 B MX358636 B MX 358636B MX 2012008300 A MX2012008300 A MX 2012008300A MX 2012008300 A MX2012008300 A MX 2012008300A MX 358636 B MX358636 B MX 358636B
Authority
MX
Mexico
Prior art keywords
nsaid
encapsulation
concentration
formulation
blando
Prior art date
Application number
MX2012008300A
Other languages
English (en)
Spanish (es)
Other versions
MX2012008300A (es
Inventor
Lopez John
Draper Peter
Vashishtha Sankalp
Klassen Nancy
Armstrong Christina
Original Assignee
Accucaps Industries Ltd Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accucaps Industries Ltd Star filed Critical Accucaps Industries Ltd Star
Publication of MX2012008300A publication Critical patent/MX2012008300A/es
Publication of MX358636B publication Critical patent/MX358636B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2012008300A 2010-01-19 2011-01-19 Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. MX358636B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2690488A CA2690488C (en) 2010-01-19 2010-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
PCT/CA2011/000059 WO2011088553A1 (en) 2010-01-19 2011-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof

Publications (2)

Publication Number Publication Date
MX2012008300A MX2012008300A (es) 2012-11-23
MX358636B true MX358636B (es) 2018-08-29

Family

ID=44303618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008300A MX358636B (es) 2010-01-19 2011-01-19 Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas.

Country Status (13)

Country Link
US (4) US9480667B2 (https=)
EP (2) EP2525789B1 (https=)
JP (2) JP5975884B2 (https=)
AU (1) AU2011207061B2 (https=)
CA (1) CA2690488C (https=)
DK (1) DK2525789T3 (https=)
ES (1) ES2880813T3 (https=)
HU (1) HUE055771T2 (https=)
MX (1) MX358636B (https=)
PL (1) PL2525789T3 (https=)
PT (1) PT2525789T (https=)
SI (1) SI2525789T1 (https=)
WO (1) WO2011088553A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
ES2784240T3 (es) * 2014-06-04 2020-09-23 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden DGLA y uso de las mismas
CN104083339A (zh) * 2014-08-04 2014-10-08 人福普克药业(武汉)有限公司 萘普生钠软胶囊及其制备方法
US10368284B2 (en) * 2014-11-12 2019-07-30 T-Mobile Usa, Inc. Quality of experience-based handover management
CN117402059A (zh) 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
JP2018520197A (ja) 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、15−hepeを含む組成物
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
US11911517B2 (en) 2018-05-16 2024-02-27 Bayer Healthcare Llc High concentration suspension formulation for cold and flu soft gel capsule medications
CN109692127A (zh) * 2019-03-15 2019-04-30 王征 一种密封小胶囊的制备方法
AU2020263295B2 (en) * 2019-04-26 2025-01-23 R.P. Scherer Technologies, Llc Mini softgel naproxen composition
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US20220233452A1 (en) * 2021-01-25 2022-07-28 R.P. Scherer Technologies, Llc Mini softgel naproxen composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
EP0741560A1 (en) * 1994-01-24 1996-11-13 The Procter & Gamble Company Process for solubilizing difficultly soluble pharmaceutical actives
US5484606A (en) * 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
US5641512A (en) 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
EP1049459B1 (en) * 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions
US6383515B2 (en) * 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
US20090318558A1 (en) * 2003-02-12 2009-12-24 Jae-Hwan Kim Solvent system of hardly soluble drug with improved dissolution rate
EP1605916A4 (en) * 2003-02-12 2012-02-22 R & P Korea Co Ltd SOLVENT SYSTEM OF A SMOOTH MEDICAMENT WITH IMPROVED ELUTION RATE
US20070053868A1 (en) * 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US7582679B2 (en) * 2006-02-03 2009-09-01 Pharmaceutics International Incorporated Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110052679A1 (en) * 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms

Also Published As

Publication number Publication date
EP3909567A1 (en) 2021-11-17
WO2011088553A1 (en) 2011-07-28
US20200046662A1 (en) 2020-02-13
US20130011470A1 (en) 2013-01-10
PT2525789T (pt) 2021-07-19
US9480667B2 (en) 2016-11-01
JP5975884B2 (ja) 2016-08-23
EP2525789A1 (en) 2012-11-28
CA2690488A1 (en) 2011-07-19
US10463637B2 (en) 2019-11-05
EP2525789A4 (en) 2014-04-30
PL2525789T3 (pl) 2022-01-03
US12605348B2 (en) 2026-04-21
CA2690488C (en) 2013-06-11
SI2525789T1 (sl) 2021-12-31
US20240139132A1 (en) 2024-05-02
EP2525789B1 (en) 2021-06-02
HUE055771T2 (hu) 2021-12-28
ES2880813T3 (es) 2021-11-25
JP2013517304A (ja) 2013-05-16
MX2012008300A (es) 2012-11-23
US20170020832A1 (en) 2017-01-26
US11896566B2 (en) 2024-02-13
AU2011207061A1 (en) 2012-07-26
DK2525789T3 (da) 2021-07-19
AU2011207061B2 (en) 2015-05-28
EP3909567B1 (en) 2026-04-29
JP2016094462A (ja) 2016-05-26

Similar Documents

Publication Publication Date Title
MX358636B (es) Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas.
CY1123023T1 (el) Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα
CR10728A (es) Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2012003204A (es) Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado.
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
CR20150402A (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
CY1123895T1 (el) Φαρμακευτικα σκευασματα λοραταδινης για εγκλεισμο σε καψακια και συνδυασμοι αυτων
HRP20181607T1 (hr) Stabilne oralne otopine za kombinirane aktivne farmaceutske sastojke
CL2014001828A1 (es) Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo.
MX367209B (es) Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
EA201691034A1 (ru) Композиции в твердой форме с замедленным высвобождением для перорального введения
MX2016014256A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.
CL2016000397A1 (es) Tratamiento contra el cáncer
CL2013003588A1 (es) Composicion farmaceutica en forma de suspension oral que comprende como principio activo una fraccion de flavonoide y como excipiente goma de xantano en la cantidad de 0,30 %p/p a 0,60 %p/p; uso para el tratamiento de la insuficiencia venosa.
AR085431A1 (es) Complejo de resinato de doxilamina
CR20160021A (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
PL395069A1 (pl) Przeciwbólowa kompozycja farmaceutyczna do podawania doustnego
EA201491995A1 (ru) Пероральная лекарственная форма
EA201590732A1 (ru) Диспергируемая таблетка
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol

Legal Events

Date Code Title Description
FG Grant or registration